Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eton PharmaceuticalsETON +5.94%58 Debt-to-Equity is 0.62 as of Jun. 2026, which is 41% above its 10-year median of 0.44. GuruFocus rates ETON with a GF Score™ of 58/100 and a GF Value™ of $24.82 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 811 Drug Manufacturers companies, Eton Pharmaceuticals ranks worse than 76.08% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Eton Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
ETON'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.44 Max: 5.05
Current: 0.62
During the past 9 years, the highest Debt-to-Equity Ratio of Eton Pharmaceuticals was 5.05. The lowest was 0.00. And the median was 0.44.
ETON's Debt-to-Equity is ranked worse than 76.08% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs ETON: 0.62
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Eton Pharmaceuticals Debt-to-Equity Related Terms
Eton Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Eton Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ETON vs COLL, ALVO, PCRX: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eton Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Eton Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eton Pharmaceuticals (ETON) has a Debt-to-Equity of 0.62 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Eton Pharmaceuticals and its competitors. This is 41% above median its historical median of 0.44. According to the industry distribution chart, Eton Pharmaceuticals ranks #617 out of 811 companies in the Drug Manufacturers industry, placing it in the top 76.1%.
Is Eton Pharmaceuticals' Debt-to-Equity too high?
Eton Pharmaceuticals' current Debt-to-Equity of 0.62 is 41% above median its 10-year median of 0.44. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Eton Pharmaceuticals' value of 0.62 is 121.4% above this industry median. Based on the distribution chart, Eton Pharmaceuticals ranks #617 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eton Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eton Pharmaceuticals' Debt-to-Equity compare to COLL and ALVO?
According to the Drug Manufacturers industry distribution chart, Eton Pharmaceuticals ranks #617 out of 811 companies for Debt-to-Equity. This places Eton Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Eton Pharmaceuticals' value of 0.62 is 121.4% above this benchmark. While the company's 10-year median is 0.44 vs. the industry median of 0.28, Eton Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eton Pharmaceuticals's current Debt-to-Equity of 0.62 is 121.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Eton Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eton Pharmaceuticals's current Debt-to-Equity is 0.62, which is 41% above median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eton Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Eton Pharmaceuticals (ETON) is currently considered Significantly Overvalued. The stock's GF Value™ is $24.82, compared to a current price of $63.47 — trading 155.7% above its estimated fair value. The current Debt-to-Equity is 0.62, which is 41% above median its 10-year median of 0.44 and 121.4% above the Drug Manufacturers industry median of 0.28. Eton Pharmaceuticals' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Eton Pharmaceuticals (ETON), the current Debt-to-Equity is 0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eton Pharmaceuticals (ETON) Overvalued in 2026?
Based on GuruFocus' analysis, Eton Pharmaceuticals stock appears to be overvalued.
The current stock price of $63.47 is trading 155.7% above its estimated GF Value™ of $24.82.
GuruFocus considers Eton Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ETON:
Debt-to-Equity: 0.62 (41% above median its 10-year median of 0.44)
GF Value™: $24.82 vs. price of $63.47 (155.7% above fair value)
Industry Position: 121.4% above the Drug Manufacturers median (#617 of 811)
No single metric tells the full story. See the ETON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
58GF Score
Get the complete analysis for ETON
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ETON has been successfully added to your 
